Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy
Abstract HER2-positive gastric cancer (GC) makes up 15–20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this...
Main Authors: | Qi Xu, Xiaoqing Xu, Haimeng Tang, Junrong Yan, Jingjing Li, Hua Bao, Xue Wu, Yang Shao, Cong Luo, Haimin Wen, Jianying Jin, Jieer Ying |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-04-01
|
Series: | Oncogenesis |
Online Access: | https://doi.org/10.1038/s41389-023-00466-2 |
Similar Items
-
In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer
by: Hui Wang, et al.
Published: (2024-04-01) -
Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01) -
Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
by: Mengqi Zhang, et al.
Published: (2022-12-01) -
Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01) -
A case of tongue swelling after S-1, oxaliplatin, and trastuzumab for HER2-positive gastric cancer
by: Taichi Abe, et al.
Published: (2023-11-01)